Takeda Pharmaceutical Company Limited

TAK· NYSE· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$16.83-1.52%

2026-08-03

Financials

Valuation Metrics

Takeda Pharmaceutical Company Limited's Market Cap is $53.18B. Ranked #309 of 3,112 in US market (top 10%), #226 of 1,667 on NYSE (top 14%), #16 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 6%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$53.18B	US#309/3,112 Sec#16/269
Revenue	$30.21B	US#221/3,112 Sec#13/269
Net Income	$1.28B	US#443/3,112 Sec#21/269
Total Assets	$97.10B	US#185/3,112 Sec#10/269
Net Assets	$48.84B	US#98/3,112 Sec#4/269
Value
P/E	41.44x	US#1,726/3,112 Sec#57/269
P/B	1.09x	US#419/3,112 Sec#19/269
PEG	0.47x	US#538/3,112 Sec#24/269
P/S	1.76x	US#1,118/3,112 Sec#24/269
EV/EBITDA	8.80x	US#589/3,112 Sec#22/269
FCF Yield	7.38%	US#816/3,112 Sec#29/269
Profitability
ROE	2.63%	US#2,013/3,112 Sec#71/269
ROA	1.32%	US#1,800/3,112 Sec#71/269
Op. Margin	10.89%	US#1,556/3,112 Sec#66/269
Revenue Growth	5.81%	US#1,667/3,112 Sec#104/269
Earnings Growth	88.39%	US#381/3,112 Sec#14/269
Financial Health
Debt Ratio	98.77%	US#1,077/3,112 Sec#169/269
Total Debt	$30.67B	US#159/3,112 Sec#11/269
FCF	$3.92B	US#190/3,112 Sec#13/269
Cash	$3.74B	US#247/3,112 Sec#15/269
Current Ratio	1.27x	US#1,900/3,112 Sec#253/269
Net Debt/EBITDA	2.96x	US#1,648/3,112 Sec#70/269
Dividend
Div. Yield	3.81%	US#407/3,112 Sec#4/269
Div. Growth	9.33%	US#559/3,112 Sec#7/269
Performance
1Y Return	18.86%	US#1,523/3,112 Sec#167/269
1M Return	0.36%	US#1,596/3,112 Sec#72/269
From 52W High	-10.95%	US#1,112/3,112 Sec#60/269
1Y MDD	-20.05%	US#680/3,112 Sec#24/269
Trading
Volume	2,965,856 shares	US#636/3,112 Sec#55/269
Trading Value	$50M	US#1,350/3,112 Sec#83/269